PatientsVille.com Logo


Alphagan Medical Research Studies

Up-to-date List of Alphagan Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Alphagan Medical Research Studies

Rank Status Study
1 Unknown  Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema
Conditions: Corneal Edema;   Visual Acuity
Interventions: Drug: Brimonidine Tartrate 0.2%;   Drug: Timolol maleate 0.5%
Outcome Measures: central corneal thickness in micrometer;   grading of corneal edema (1-3)
2 Unknown  Effect of Brimonidine on Corneal Thickness
Condition: Impact of Brimonidine on the Cornea
Interventions: Drug: brimonidine 0.1%;   Drug: placebo
Outcome Measures: corneal thickness;   intraocular pressure
3 Unknown  Aqueous Humor Dynamics and Brimonidine
Condition: Intraocular Pressure
Interventions: Drug: Brimonidine;   Drug: Artificial tears
Outcome Measure: Aqueous Humor Dynamics
4 Unknown  Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy
Condition: Glaucoma
Interventions: Drug: Brimonidine;   Drug: Placebo Lotion
Outcome Measures: Intraocular Pressure;   Heart Rate;   Blood Pressure
5 Unknown  Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism
Conditions: Ocular Physiology;   Intraocular Pressure
Intervention: Drug: Brimonidine 0.2 %
Outcome Measures: Intraocular pressure (IOP);   alpha-2B receptor genotyping
6 Recruiting Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study
Condition: Acne Rosacea
Interventions: Drug: Azelaic acid 15%;   Drug: Brimonidine 0.33%
Outcome Measures: Change in Investigator Global Assessment;   Lesion counts;   Clinician's Erythema assessment;   Erythema VAS Assessment (Subject);   Dermatology Life Quality Index (DLQI)
7 Recruiting Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects With Ocular Redness.
Condition: Hyperemia
Interventions: Drug: Brimonidine Tartrate;   Drug: Vehicle
Outcome Measures: Ocular Redness - Investigator;   Ocular Redness - Participant
8 Not yet recruiting Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Subjects.
Condition: Hyperemia
Interventions: Drug: Brimonidine Tartrate;   Drug: Vehicle
Outcome Measures: Adverse Events;   Drop Comfort;   Alertness
9 Unknown  Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Conditions: Retina;   Ocular Physiology
Interventions: Drug: latanoprost 0.005% + timolol 0,5% fixed combination;   Drug: brimonidine 0,2% + timolol 0,5% fixed combination
Outcome Measures: Optic disc blood flow measured with laser Doppler flowmeter (rel units);   Intraocular pressure (mmHg);   Retrobulbar flow velocities as measured with color Doppler imaging (cm/s);   Mean defect of visual field measured with automated perimetry (dB);   Corneal thickness as measured with pachymetry (µm)
10 Unknown  Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma
Condition: Normal Tension Glaucoma
Interventions: Drug: Brimonidine/Timolol mixed combination;   Drug: Timolol
Outcome Measure: Change from baseline in intraocular pressure at 12 weeks
11 Unknown  Intraocular Pressure Control After Anterior Segment Laser - Comparison Between 2 Drugs
Condition: Glaucoma, Narrow Angle
Intervention: Procedure: YAG laser peripheral iridotomy
Outcome Measure: intra-ocular pressure increase
12 Recruiting A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration
Conditions: Geographic Atrophy;   Macular Degeneration
Interventions: Drug: 400 µg Brimonidine Implant;   Other: Sham
Outcome Measures: Change from Baseline in Atrophic Lesion Area in the Study Eye;   Change from Baseline in Retinal Sensitivity in the Study Eye;   Change from Baseline in Low Luminance Best Corrected Visual Acuity (BCVA) in the Study Eye;   Change from Baseline in BCVA in the Study Eye
13 Recruiting Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Conditions: Glaucoma, Open-Angle;   Ocular Hypertension
Interventions: Drug: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy);   Drug: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
Outcome Measures: Intraocular Pressure (IOP);   IOP
14 Unknown  Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans
Conditions: Glaucoma;   Ocular Physiology;   Regional Blood Flow
Interventions: Drug: Timolol (drug);   Drug: dorzolamide (drug);   Drug: brimonidine (drug);   Device: Laser Doppler flowmetry;   Device: Goldmann applanation tonometer;   Procedure: Suction cup method
Outcome Measures: Ocular perfusion pressure - ONH blood flow relationship;   Blood pressure, heart rate
15 Unknown  Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma
Condition: Glaucoma
Intervention: Drug: glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)
Outcome Measures: Intraocular pressure after Ahmed valve implantation for glaucoma;   rate of hypertensive phase after Ahmed valve implantation for glaucoma
16 Unknown  Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty
Conditions: Glaucoma;   Ocular Hypertension
Interventions: Drug: brimonidine 0.1%;   Drug: Apraclonidine 0.5%
Outcome Measures: Postoperative IOP;   Overall IOP reduction post SLT
17 Unknown  Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves
Condition: Glaucoma
Intervention: Drug: Aqueous Suppressant Eye Drops
Outcome Measures: Intraocular pressure;   Hyperencapsulation phase (HEP);   Qualified Ahmed Glaucoma Valve success;   Absolute Ahmed Glaucoma Valve success;   Number of glaucoma medications
18 Unknown  Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure Glaucoma
Condition: Glaucoma
Interventions: Procedure: Selective Laser Trabeculoplasty;   Drug: Travoprost/ Timolol/ Azopt/ Brimonidine
Outcome Measure: Intraocular Pressure
19 Recruiting Micropulse Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty for Treatment of Open Angle Glaucoma
Condition: Open Angle Glaucoma
Interventions: Device: Micropulse Laser Trabeculoplasty;   Device: Selective Laser Trabeculoplasty
Outcome Measures: Intraocular pressure reduction;   incidence of intraocular inflammation
20 Unknown  Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)
Condition: Glaucoma
Interventions: Drug: Cosopt;   Drug: Combigan
Outcome Measure: Change in retinal blood flow with increase in perfusion pressure due to posture change

These studies may lead to new treatments and are adding insight into Alphagan etiology and treatment.

A major focus of Alphagan research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Alphagan